These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38527504)

  • 21. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
    Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
    BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
    An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical Characteristics and Prognosis of
    Li M; Zheng YZ; Li J; LE SH; Zheng H; Chen ZS; Weng KZ; Zhuang SQ; Wu XG; Wen H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):973-979. PubMed ID: 37551464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
    Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
    Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
    Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].
    Mei YY; Li ZG; Zhang Y; Zhang WL; Zhang PW; Wang N; Huang DS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):66-71. PubMed ID: 28245377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
    Wang Y; Zeng HM; Zhang LP
    Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
    Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
    Jiang MY; Gao W; Gao J; Ling J; Pan J; Xiao PF; Lu J; He HL; Wang Y; Li J; Li JQ; Chai YH; Sun YN; Hu SY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):12-17. PubMed ID: 35123597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
    Zhu Y; Zhu Y; Miao L; Jia T; Mao J; Xue L; Wang Y
    Technol Cancer Res Treat; 2023; 22():15330338231165866. PubMed ID: 36959735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
    Cai JY; Xue HL; Chen J; Shen SH; Pan C; Wang X; Zhou M; Tang YJ; Gao YJ; Wang JM; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):456-60. PubMed ID: 27256235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
    Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
    Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.